lenvatinib has been researched along with Hemoperitoneum* in 1 studies
1 other study(ies) available for lenvatinib and Hemoperitoneum
| Article | Year |
|---|---|
Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib.
We herein report two patients with hepatocellular carcinoma (HCC) who exhibited intraabdominal bleeding caused by tumor rupture soon after lenvatinib initiation. A hypervascular nodule was present in the lateral segment manifesting extrahepatic protrusion in an 81-year-old-man and in the caudate lobe, which was completely occupied by the tumor, in an 83-year-old-man. Both patients were given lenvatinib, and epigastralgia occurred suddenly three and five days later. Computed tomography revealed high-attenuation areas suggesting bleeding around the left and caudate lobes. Considering the strong antiangiogenic effects by lenvatinib, transcatheter arterial embolization should be performed before lenvatinib initiation in patients with subcapsular HCC. Topics: Aged, 80 and over; Carcinoma, Hepatocellular; Hemoperitoneum; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Rupture | 2022 |